Guardant Health [GH] vs RadNet [RDNT] Detailed Stock Comparison
Guardant Health
NASDAQ
Loading...
RadNet
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Guardant Health wins in 9 metrics, RadNet wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Guardant Health | RadNet | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.26 | 1,425.75 | Guardant Health |
| Price-to-Book Ratio | -22.08 | 4.45 | Guardant Health |
| Debt-to-Equity Ratio | -4.37 | 153.63 | Guardant Health |
| PEG Ratio | -20.01 | 71.15 | Guardant Health |
| EV/EBITDA | -18.07 | 23.51 | Guardant Health |
| Profit Margin (TTM) | -49.93% | -1.73% | RadNet |
| Operating Margin (TTM) | -45.75% | -3.73% | RadNet |
| Return on Equity | 312.48% | 0.33% | Guardant Health |
| Return on Assets (TTM) | -19.57% | 1.65% | RadNet |
| Free Cash Flow (TTM) | $-274.94M | $1.29M | RadNet |
| 1-Year Return | 87.00% | -15.07% | Guardant Health |
| Price-to-Sales Ratio (TTM) | 8.16 | 2.19 | RadNet |
| Enterprise Value | $7.57B | $5.27B | Guardant Health |
| EV/Revenue Ratio | 9.14 | 2.82 | RadNet |
| Gross Profit Margin (TTM) | 65.01% | 3.80% | Guardant Health |
| Revenue per Share (TTM) | $7 | $25 | RadNet |
| Earnings per Share (Diluted) | $-3.35 | $-0.43 | RadNet |
| Beta (Stock Volatility) | 1.44 | 1.43 | RadNet |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Guardant Health vs RadNet Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Guardant Health | 7.62% | 30.93% | 6.71% | 30.11% | 22.14% | 70.70% |
| RadNet | 1.58% | -2.43% | -3.54% | -5.36% | -14.42% | -23.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Guardant Health | 87.00% | 0.09% | -36.54% | 85.72% | 85.72% | 85.72% |
| RadNet | -15.07% | 139.93% | 209.87% | 599.34% | 2,554.73% | 7,747.06% |
Performance & Financial Health Analysis: Guardant Health vs RadNet
| Metric | GH | RDNT |
|---|---|---|
| Market Information | ||
| Market Cap | $6.76B | $4.10B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 4,168,170 | 750,160 |
| 90 Day Avg. Volume | 2,645,913 | 700,530 |
| Last Close | $54.23 | $53.36 |
| 52 Week Range | $20.14 - $54.62 | $45.00 - $93.65 |
| % from 52W High | -0.71% | -43.02% |
| All-Time High | $181.07 (Feb 08, 2021) | $93.65 (Nov 11, 2024) |
| % from All-Time High | -70.05% | -43.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.09% |
| Quarterly Earnings Growth | 0.31% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.50% | -0.02% |
| Operating Margin (TTM) | -0.46% | -0.04% |
| Return on Equity (TTM) | 3.12% | 0.00% |
| Debt to Equity (MRQ) | -4.37 | 153.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.45 | $11.98 |
| Cash per Share (MRQ) | $4.19 | $9.56 |
| Operating Cash Flow (TTM) | $-238,546,000 | $257.42M |
| Levered Free Cash Flow (TTM) | $-131,174,000 | $109.53M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Guardant Health vs RadNet
| Metric | GH | RDNT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.26 | 1,425.75 |
| Forward P/E | -20.01 | 71.15 |
| PEG Ratio | -20.01 | 71.15 |
| Price to Sales (TTM) | 8.16 | 2.19 |
| Price to Book (MRQ) | -22.08 | 4.45 |
| Market Capitalization | ||
| Market Capitalization | $6.76B | $4.10B |
| Enterprise Value | $7.57B | $5.27B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.14 | 2.82 |
| Enterprise to EBITDA | -18.07 | 23.51 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 1.43 |
| Book Value per Share (MRQ) | $-2.45 | $11.98 |
Financial Statements Comparison: Guardant Health vs RadNet
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GH | RDNT |
|---|---|---|
| Revenue/Sales | $203.47M | $471.40M |
| Cost of Goods Sold | $74.72M | $453.48M |
| Gross Profit | $128.75M | $17.92M |
| Research & Development | $88.52M | N/A |
| Operating Income (EBIT) | $-111.04M | $-17.56M |
| EBITDA | $-83.84M | $28.23M |
| Pre-Tax Income | $-94.87M | $-33.14M |
| Income Tax | $290,000 | $-3.40M |
| Net Income (Profit) | $-95.16M | $-29.74M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GH | RDNT |
|---|---|---|
| Cash & Equivalents | $698.57M | $717.32M |
| Total Current Assets | $927.03M | $1.02B |
| Total Current Liabilities | $225.75M | $505.40M |
| Long-Term Debt | $1.28B | $1.66B |
| Total Shareholders Equity | $-250.79M | $1.14B |
| Retained Earnings | $-2.67B | $-114.71M |
| Property, Plant & Equipment | $140.50M | $1.37B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GH | RDNT |
|---|---|---|
| Operating Cash Flow | $-49.41M | $14.88M |
| Capital Expenditures | $-4.46M | $-48.81M |
| Free Cash Flow | $-67.15M | $-7.35M |
| Debt Repayment | N/A | $-6.72M |
| Common Stock Repurchase | $-45.01M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GH | RDNT |
|---|---|---|
| Shares Short | 9.58M | 6.48M |
| Short Ratio | 4.80 | 10.37 |
| Short % of Float | 0.08% | 0.10% |
| Average Daily Volume (10 Day) | 4,168,170 | 750,160 |
| Average Daily Volume (90 Day) | 2,645,913 | 700,530 |
| Shares Outstanding | 123.99M | 74.04M |
| Float Shares | 119.55M | 67.43M |
| % Held by Insiders | 0.05% | 0.13% |
| % Held by Institutions | 0.99% | 0.92% |
Dividend Analysis & Yield Comparison: Guardant Health vs RadNet
| Metric | GH | RDNT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |